Preliminary results of pamiparib (BGB-290), a PARP1/2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors

被引：0
|
作者：
Johnson, M. [1 ]
Galsky, M. [2 ]
Barve, M. [3 ]
Goel, S. [4 ]
Park, H. [5 ]
Du, B. [6 ]
Mu, S. [7 ]
Ramakrishnan, V. [8 ]
Wood, K. [9 ]
Wang, V. [10 ]
Lakhani, N. [11 ]
机构：
[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[2] Icahn Sch Med Mt Sinai, Hematol & Med Oncol, New York, NY 10029 USA
[3] Mary Crowley Canc Res, Med Oncol, Dallas, TX USA
[4] Montefiore Med Ctr, Med Oncol, 111 E 210th St, Bronx, NY 10467 USA
[5] Washington Univ, Med Oncol, St Louis, MO USA
[6] Beigene USA Inc, Pharmacovigilance & Drug Safety, San Mateo, CA USA
[7] BeiGene USA Inc, Clin Pharmacol, Ft Lee, NJ USA
[8] BeiGene USA Inc, CDx & Biomarker Dev, San Mateo, CA USA
[9] BeiGene USA Inc, Clin Sci, San Mateo, CA USA
[10] BeiGene USA Inc, Biostat, San Mateo, CA USA
[11] START Midwest, Dev Therapeut, Grand Rapids, MI USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
421P
引用
收藏
页码：138 / 138
页数：1
相关论文
共 50 条
  • [1] Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (Id) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours
    Stradella, A.
    Johnson, M. L.
    Goel, S.
    Chandana, S. R.
    Galsky, M. D.
    Calvo, E.
    Moreno, V.
    Park, H.
    Arkenau, H. -T.
    Cervantes, A.
    Farinas Madrid, L.
    Mileshkin, L.
    Plummer, R.
    Evans, J.
    Horvath, L.
    Prawira, A.
    Pelham, R. J.
    Mu, S.
    Andreu-Vieyra, C.
    Barve, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 166 - +
  • [2] Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ)
    Stradella, A.
    Johnson, M.
    Goel, S.
    Chandana, S. R.
    Galsky, M. D.
    Calvo, E.
    Moreno, V.
    Park, H.
    Arkenau, T.
    Cervantes, A.
    Farinas-Madrid, L.
    Mileshkin, L.
    Fu, S.
    Plummer, R.
    Evans, J.
    Horvath, L.
    Prawira, A.
    Qu, K.
    Pelham, R.
    Barve, M. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S465 - S466
  • [3] Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results
    Voskoboynik, M.
    Mileshkin, L.
    Gan, H.
    Millward, M.
    Au-Yeung, G.
    Meniawy, T. M.
    Kichenadasse, G.
    Zhang, K.
    Zhang, M.
    Mu, S.
    Lickliter, J. D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] Phase 1b/2 study to assess the safety, tolerability, and clinical activity of BGB-290 in combination with temozolomide in patients with locally advanced or metastatic solid tumors
    Johnson, M.
    Benson, B.
    Wei, R.
    Brachmann, R.
    Galsky, M. D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors.
    Lickliter, Jason D.
    Gan, Hui Kong
    Meniawy, Tarek
    Yang, Jason
    Wang, Lai
    Luo, Lusong
    Lu, Ni
    Millward, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.
    Friedlander, Michael
    Meniawy, Tarek
    Markman, Ben
    Mileshkin, Linda R.
    Harnett, Paul
    Millward, Michael
    Lundy, Joanne
    Freimund, Alison E.
    Norris, Christie
    Wu, John
    Paton, Virginia
    Wang, Lai
    Gao, Bo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [7] A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.
    Friedlander, Michael
    Meniawy, Tarek
    Markman, Ben
    Mileshkin, Linda R.
    Harnett, Paul R.
    Millward, Michael
    Lundy, Joanne
    Freimund, Alison E.
    Norris, Christie
    Mu, Song
    Wu, John
    Paton, Virginia E.
    Wang, Lai
    Gao, Bo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM)
    Shih, Kent
    Schiff, David
    Kim, Lyndon
    Battiste, James
    Campian, Jian
    Puduvalli, Vinay
    Wen, Patrick
    Cloughesy, Timothy
    van den Bent, Martin
    Pirzkall, Andrea
    Wood, Katie
    Wei, Rachel
    Du, Bing
    Mu, Song
    Ramakrishnan, Vanitha
    Walbert, Tobias
    NEURO-ONCOLOGY, 2018, 20 : 17 - 18
  • [9] Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors
    Stradella, Agostina
    Johnson, Melissa
    Goel, Sanjay
    Park, Haeseong
    Lakhani, Nehal
    Arkenau, Hendrik-Tobias
    Galsky, Matthew D.
    Calvo, Emiliano
    Baz, Vicente
    Moreno, Victor
    Saavedra, Omar
    Luen, Stephen J.
    Mu, Song
    Wan, Qiting
    Chang, Victoria
    Zhang, Wa
    Barve, Minal
    CANCER MEDICINE, 2024, 13 (13):
  • [10] First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors.
    Plummer, R
    Middleton, M
    Wilson, R
    Jones, C
    Evans, J
    Robson, L
    Steinfeldt, H
    Kaufman, R
    Reich, S
    Calvert, AH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 208S - 208S
12345